Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Chubb
Daiichi Sankyo
US Department of Justice
Julphar
Chinese Patent Office

Generated: May 26, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,645,460

« Back to Dashboard

Which drugs does patent 7,645,460 protect, and when does it expire?

Patent 7,645,460 protects ATELVIA and is included in one NDA.

This patent has seventy-six patent family members in thirty-one countries.

Summary for Patent: 7,645,460
Title:Dosage forms of risedronate
Abstract:Oral dosage forms of a risedronate comprised of a safe and effective amount of a pharmaceutical composition comprising risedronate, a chelating agent, and, means for effecting delayed release of the risedronate and the chelating agent in the small intestine provide immediate release of the pharmaceutical composition to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between risedronate and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, the present invention effects delivery of risedronate and the chelating agent to the small intestine, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies.
Inventor(s): Dansereau; Richard John (Cincinnati, OH), Burgio, Jr.; David Ernest (Liberty Township, OH)
Assignee: The Procter & Gamble Company (Cincinnati, OH)
Application Number:11/286,875
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,645,460
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,645,460
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Delivery; Use;

Drugs Protected by US Patent 7,645,460

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Apil ATELVIA risedronate sodium TABLET, DELAYED RELEASE;ORAL 022560-001 Oct 8, 2010 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Baxter
Express Scripts
Federal Trade Commission
Harvard Business School
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.